Sight Sciences, Inc. (SGHT) key performance indicators and operating metrics (15 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Gross Margin | 86.20 percent | FY2026-Q1 |
| Adjusted Operating Expenses | 21.16M | FY2026-Q1 |
| Interventional Dry Eye Active Customers | 96.00 | FY2026-Q1 |
| Interventional Dry Eye Gross Margin | 72.10 percent | FY2026-Q1 |
| Interventional Dry Eye Lid Treatment Units Sold | 1.53K | FY2026-Q1 |
| Interventional Glaucoma Active Customers | 1.18K | FY2026-Q1 |
| Interventional Glaucoma Gross Margin | 87.20 percent | FY2026-Q1 |
| Interventional Glaucoma Revenue | 18.34M | FY2026-Q1 |
| Surgical Glaucoma Segment Revenue | 19.65M | FY2025-Q4 |
| Dry Eye Segment Revenue | 700K | FY2025-Q4 |
| Surgical Glaucoma Segment Gross Margin | 87.00 percent | FY2025-Q3 |
| Dry Eye Segment Gross Margin | 38.00 percent | FY2025-Q3 |
| Active Dry Eye Customers | 39.00 | FY2025-Q2 |
| Dry Eye Lid Treatment Units Sold | 1.14K | FY2025-Q2 |
Back to SGHT overview · SGHT earnings · SGHT holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.